26.49 USD
↘ 0.99 (3.60%)AT CLOSE (11:59 AM EDT)
Neurogene, Inc. Common Stock
NGNENASDAQ • USD
26.42
↘ 0.08 (0.28%)
POST MARKET (AS OF 07:54 PM EDT)
Post Market
AS OF 07:54 PM EDT
26.42
↘ 0.08 (0.28%)
Market: CLOSED
Open?$27.48
High?$27.50
Low?$26.00
Prev. Close?$27.48
Volume?67.4K
Avg. Volume?135.9K
VWAP?$26.50
Rel. Volume?0.50x
Bid / Ask
Bid?$22.49 × 100
Ask?$30.00 × 100
Spread?$7.51
Midpoint?$26.24
Valuation & Ratios
Market Cap?418.6M
Shares Out?15.8M
Float?9.7M
Float %?62.9%
P/E Ratio?N/A
P/B Ratio?1.76
EPS?-$6.24
Dividend?0.00%
Ex-Dividend?N/A
Neurogene, Inc. Common Stock (NGNE) is currently trading at $26.49. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest NGNE is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Themes
Employees
131
Market Cap
418.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2023-12-19
Address
535 W 24TH STREET
NEW YORK, NY 10011
Phone: (877) 237-5020
NEW YORK, NY 10011
Phone: (877) 237-5020
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?10
Piotroski F-Score?0/9Weak
Altman Z-Score?7.51Safe
Confidence?45%Low
Short InterestSqueeze Risk
Short % of Float?37.00%Squeeze Risk
Short Interest?3.6M
Days to Cover?24.7
Free Float9.7M
Avg Daily Volume146.2K
Settlement Date2026-05-15
Financial Health
Current Ratio?13.08Strong
Quick Ratio?13.08Strong
Cash Ratio?6.58Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.76CHEAP▾
Peers100
S&P81
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.7CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-41.5%WEAK▾
S&P3
ROA?-37.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-83202000
Enterprise Value?$294.4M
Fundamentals ratios updated end of day